|
|
  |
PROGRAM
7th International Winter Conference on
|
Thursday, 9th of December 2010
|
14:30
|
WELCOME AND INTRODUCTION
Manfred Windisch (Organizer) and Reinhold Schmidt (President of the Austrian Alzheimer Society)
Chair: Ezio Giacobini
|
|
14:45
|
OPENING LECTURE
Where do we stand with the validation of diagnostic criteria for early AD?
Bruno Dubois
|
|
15:15
|
KEYNOTE LECTURE
Is amyloid imaging useful for diagnosis of early AD and can it be applied to test new therapies?
Agneta Nordberg
|
|
15:40
|
General discussion
|
|
16:00
|
Coffee break
|
|
Discussion
Panel 1
|
CLINICAL BACKGROUND – THE DEFINITION OF THE PROBLEM
Chair: Bruno Dubois
|
|
16:20
|
Vascular co-morbidity in mild cognitive impairment
Reinhold Schmidt
|
|
16:40
|
Genetic factors modulating cerebrovascular disease
Helena Schmidt
|
|
17:00
|
Assessing disease modification in AD by means of fMRI
Peter Kapeller
|
|
17:20
|
Conventional and advanced MRI techniques for diagnosis and monitoring of AD
Stefan Ropele
|
|
17:40
|
Amyloid PET imaging with florbetapir F18 to identify Alzheimer’s disease pathology prior to dementia
Chris M. Clark
|
|
18:00
|
Biomarker-based approaches to diagnose prodromal Alzheimer's disease and to detect treatment effects - opportunities and challenges
Henrik Zetterberg
|
|
18:20
|
The measure of Aβ pool in blood may be an effective screening and monitoring tool for clinical trials in Alzheimer’s disease
Pedro Pesini
|
|
18:40
|
General discussion
|
|
19:00
|
Cocktail reception
|
|
19:30
|
Dinner
|
Friday, 10th of December 2010
|
Discussion
Panel 2
|
COGNITIVE TESTING IN EARLY AD
Chair: Bruno Dubois
|
|
08:30
|
Prodromal dementia: How sensitive is neuropsychology?
Thomas Benke
|
|
08:50
|
Detecting cognitive deficits and measuring cognitive change in prodromal Alzheimer’s disease
John Harrison
|
|
09:10
|
New Methodological Strategies for Clinical Trials in Mild Cognitive Impairment
Janet Williams |
| 09:30 | General discussion |
|
09:50
|
Coffee break
|
|
Discussion
Panel 3
|
CLINICAL BACKGROUND CONTINUED
Chair: Peter Kapeller
|
|
10:10
|
Apathy: Clinical and therapeutic implications
Anton Alvarez
|
|
10:30
|
“Reversible Alzheimer Dementia” in a cohort-study
Peter Fischer
|
|
10:50
|
Alzheimer bubble – fiction or reality?
Klaus-Christian Steinwachs
|
|
11:10
|
Early diagnosis of AD – no treatment!?
Hermann-Josef Gertz
|
|
11:40
|
General discussion
|
|
12:00
|
NETWORKING SESSION
|
|
14:30
|
SPECIAL LECTURE: THE INVESTORS POINT OF VIEW
Chair: Kees Been
|
|
|
Despite setbacks, Wall Street continues to embrace Alzheimer's drug candidates - too big to fail
Elemer Piros
|
|
15:00
|
General discussion
|
|
Discussion
Panel 4
|
PRECLINICAL TESTING
Chair: Eliezer Masliah
|
|
15:25
|
Do we need new animal models for preclinical testing of new therapies for prodromal AD?
Manfred Windisch
|
|
15:45
|
General discussion
|
|
Discussion
Panel 5
|
The Immunotherapy of neurodegenerative disorders
Chair: Peter Dal-Bianco
|
|
16:00
|
Can Alzheimer's Disease be prevented by a vaccine?
Cindy Lemere
|
|
16:20
|
Immunotherapy of Neurodegenerative Diseases
Roger Nitsch
|
|
16:40
|
Monoclonal antibodies for treatment of early AD – what do we know?
Hansruedi Loetscher
|
|
17:00
|
SupraAntigen vaccine technology - A Novel T Cell Independent Liposomal Amyloid-beta Vaccine for the Treatment of Alzheimer’s Disease
Andreas Muhs
|
|
17:20
|
General discussion
|
|
17:40
|
Coffee break
|
|
Discussion
Panel 6
|
The Immunotherapy of neurodegenerative disorders
Chair: Hansruedi Loetscher
|
|
18:00
|
Development of AFFITOPE vaccines for the treatment of Alzheimer’s disease – Results from clinical phase I
Achim Schneeberger
|
|
18:20
|
Genetic and neuropathological links of alpha synuclein with Parkinson’s disease and related dementias
Philipp Kahle |
|
18:40
|
AFFITOPE based immunotherapeutic strategies for Parkinson’s disease
Markus Mandler
|
|
19:00
|
Prion-like dissemination of a-synuclein in Parkinson's Disease; prospects for immunotherapy developments
Eliezer Masliah
|
|
19:20
|
General discussion
|
|
20:00
|
Dinner
|
Saturday, 11th of December 2010
|
MORNING SESSION
|
SMALL MOLECULES
Chair: Roger Nitsch
|
|
08:30
|
Update on small molecules against AD hallmarks: Challenges and perspectives
Abraham Fisher
|
|
09:00
|
General discussion
|
|
Discussion
Panel 7
|
Gamma Secrtetases-Modulators and InhiBItors
Chair: Israel Hanin
|
|
09:20
|
Measuring Abeta peptides in plasma and CSF: not always what you expect
Randy Slemmon
|
|
09:40
|
Update: Gamma-secretase modulators: a treatment for early AD
Corinne Augelli-Szafran
|
|
10:00
|
Treatment with the gamma secretase modulator EVP-0015962 improves cognitive deficits and reduces plaque load in tg2576 mice
Kathy Rogers
|
|
10:20
|
Pharmacokinetic and pharmacodynamic analysis of the gamma-secretase modulator EVP-0015962
Kevin Felsenstein
|
|
10:40
|
General discussion
|
|
11:00
|
Coffee break
|
|
Discussion
Panel 8
|
Alternative ways to Target A-Beta
Chair: Gerhard Koenig
|
|
11:20
|
Will there ever be a therapy for AD based on ApoE?
Danny Michaelson
|
|
11:40
|
Novel anti-amyloid small molecules as potential disease-modifying therapies for Alzheimer’s disease
Mark Treherne, David Scopes
|
|
12:00
|
Discovery of novel HDAC- inhibitors for CNS indications
Holger Patzke
|
| 12:20 | NPT001, a novel approach for amyloid plaque disaggregation Kimberley Gannon |
|
12:40
|
General discussion
|
|
13:00
|
NETWORKING SESSION
|
| 14:20 | SPECIAL LECTURE: THE CEO’s POINT OF VIEW Chair: Klaus-Christian Steinwachs |
| Developing drugs for neuro-degenerative diseases, challenges and opportunities for Biotech companies Kees Been |
|
| 14:40 | General discussion |
|
Discussion
Panel 9
|
GLUTAMINYL CYCLASES – TARGETS TO TREAT ALZHEIMER’S DISEASE AND NEUROINFLAMMATION
Chair: Hans-Ulrich Demuth
|
|
15:00
|
Introduction
Hans-Ulrich Demuth
|
|
15:10
|
QC-expression enhances pGlu-Abeta formation and mediates phenotypic changes in transgenic mice
Stephan Schilling
|
|
15:30
|
Glutaminyl Cyclase Isoenzymes - Involvement in distinct cellular (neuroinflammatory) pathways
Holger Cynis
|
|
15:50
|
The development of inhibitors for glutaminyl cyclase as drugs for Alzheimer’s disease (AD)
Ulrich Heiser
|
|
16:10
|
Biomarker development to accompany preclinics and clinics of QC/isoQC inhibitors in AD and neuroinflammation
Martin Kleinschmidt
|
|
16:30
|
General discussion
|
|
16:50
|
Coffee break
|
|
Discussion
Panel 10
|
TAU PROTEIN DIRECTED THERAPIES
Chair: Christian Bancher
|
|
17:10
|
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer’s disease
Michal Novak
|
|
17:30
|
Targets and biomarkers for disease modification of Alzheimer's disease Christian Czech |
|
17:50
|
Targeting tau RNA alternative splicing for frontotemporal dementia and related disorders
Michael Wolfe
|
|
18:10
|
General discussion
|
|
Discussion
Panel 11
|
NICOTINIC DRUGS
Chair: Abraham Fisher
|
|
18:30
|
Mechanism of action of EVP-6124, a nicotinic alpha7 agonist in phase II development for Alzheimer’s disease & schizophrenia, surprises & synergies Gerhard Koenig |
|
18:50
|
Are we ready to test new therapies in prodromal AD? – THE ANSWER
Ezio Giacobini |
|
19:10
|
General discussion
|
|
20:00
|
Dinner
|
Sunday, 12th of December 2010
|
Round table discussion
from 09:00 am to 11:00 am
“Start of treatment of AD – Is early early enough?”Moderation: Ezio Giacobini and Abraham Fisher
OPEN DISCUSSION – NETWORKING ACTIVITIES
|
The 10th International Conference on Alzheimer´s & Parkinson´s Diseases
© 2010 by JSW Lifesciences GmbH